Becton, Dickinson and Company $BDX Stock Acquired by New York Life Investment Management LLC

New York Life Investment Management LLC increased its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 22.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,960 shares of the medical instruments supplier’s stock after purchasing an additional 8,599 shares during the quarter. New York Life Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $8,406,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Maryland Capital Advisors Inc. lifted its holdings in Becton, Dickinson and Company by 13,900.0% in the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 139 shares in the last quarter. Meeder Asset Management Inc. grew its stake in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 102 shares in the last quarter. Main Street Group LTD acquired a new stake in shares of Becton, Dickinson and Company during the first quarter valued at about $29,000. Bell Investment Advisors Inc purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $29,000. Finally, Kelleher Financial Advisors purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $30,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas Polen, Jr. sold 2,993 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $210.00, for a total transaction of $628,530.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at $23,134,230. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 3,310 shares of company stock worth $688,650. 0.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

BDX has been the topic of several recent analyst reports. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Citigroup raised their price objective on Becton, Dickinson and Company from $208.00 to $241.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Bank of America lifted their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Jefferies Financial Group reissued a “buy” rating and set a $242.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, November 5th. Finally, UBS Group began coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $197.47.

View Our Latest Research Report on BDX

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $215.72 on Friday. The stock has a market cap of $59.44 billion, a P/E ratio of 16.26, a P/E/G ratio of 3.59 and a beta of 0.22. The firm’s 50-day simple moving average is $190.29 and its 200 day simple moving average is $170.48. Becton, Dickinson and Company has a fifty-two week low of $140.11 and a fifty-two week high of $216.85. The company has a quick ratio of 0.54, a current ratio of 0.87 and a debt-to-equity ratio of 0.54.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. The firm had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. During the same quarter in the prior year, the firm posted $3.96 EPS. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post 13.21 EPS for the current year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock buyback plan on Thursday, November 5th that permits the company to repurchase 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase up to 3.6% of its shares through open market purchases. Share buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Thursday, December 10th will be paid a dividend of $1.06 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Thursday, December 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 101.45%.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Featured Articles

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.